Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
4/2018 ceased to operate
NeurOptic
NeurOptic Overview
NeurOptic's lead product for glaucoma is based on an FDA-approved drug indicated as therapy for neurodegenerative disease. NeurOptic is developing an ophthalmic formulation for glaucoma treatment established on the prolonged residence time of a monoamine oxidase inhibitor on the ocular surface and providing sustained delivery and constant effect of the drug for two months. Preliminary pre-clinical studies showed that the novel topical treatment of NeurOptic's product exerted a significant effect on high levels of intraocular pressure and may prevent neuronal damage in the eye.